Interactions of platelets with Synthocytes, a novel platelet substitute.
A platelet substitute, Synthocytes, is being developed for the prevention and treatment of thrombocytopenia. Synthocytes are composed of fibrinogen adsorbed on heat stabilised albumin microcapsules of defined size. The purpose of this study was to perform experiments in vitro to investigate the capacity of Synthocytes to interact with platelets, one of the means through which Synthocytes may contribute to haemostatic plug formation in vivo. Synthocytes were found to interact with platelets as shown by platelet aggregation assays and measurements of [(14)C]5HT release from platelets in whole blood and platelet-rich plasma. Platelet-Synthocytes co-aggregate formation was demonstrated directly using flow cytometry and the presence of activated platelets in these co-aggregates was demonstrated using an antibody to P-selectin. Synthocytes enhanced platelet responsiveness to conventional aggregating agents such as ADP. Indeed, antagonists of the action of ADP on platelets inhibited the direct effects of Synthocytes on platelets in whole blood, as did a GPIIb/IIIa antagonist. Enhancement of annexin V binding was also observed, indicative of increased pro-coagulant activity. Experiments performed with control microcapsules (lacking fibrinogen) confirmed the importance of fibrinogen in the interactions that occurred. The results suggest that fibrinogen on the surface of Synthocytes can interact with GPIIb/IIIa on platelets to induce platelet activation, secretory activity and aggregation, and that ADP contributes to this process. This initial interaction renders platelets more susceptible to the stimulatory effects of other platelet-activating agents. It is considered likely that in the clinical setting of thrombocytopenia any interaction between Synthocytes and residual platelets that are present may contribute to primary haemostasis.
Centre for Vascular Research, University of Nottingham, Cardiovascular Medicine, Queen's Medical Centre, Nottingham NG7 2UH, UK.
A R
AR
Davies
H M
HM
Judge
J A
JA
May
J R
JR
Glenn
S
S
Heptinstall
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000418:Albumins / Q000737:chemistry; D001792:Blood Platelets / Q000166:cytology / Q000502:physiology*; D001802:Blood Substitutes / Q000737:chemistry / Q000494:pharmacology*; D002214:Capsules / Q000737:chemistry / Q000494:pharmacology; D004347:Drug Interactions; D005260:Female; D005340:Fibrinogen / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D005434:Flow Cytometry; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010979:Platelet Function Tests; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D013921:Thrombocytopenia / Q000628:therapy
D000418:Albumins; D001802:Blood Substitutes; D002214:Capsules; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D012701:Serotonin; D000244:Adenosine Diphosphate; D005340:Fibrinogen